Peptides and the Reward System

Neuropeptides and Compulsive Behavior: A Shared Biology

12 min read|March 24, 2026

Peptides and the Reward System

5+ peptide systems

Opioid peptides, ghrelin, orexin, GLP-1, and oxytocin all converge on the brain's reward circuitry, and disruptions in any of them can drive compulsive behavior.

Jin et al., Frontiers in Endocrinology, 2023

View as image

Compulsive eating, compulsive gambling, and compulsive drug use look different from the outside. From the inside of the brain, they share remarkable biological overlap. The same neuropeptide systems that regulate hunger, stress, and pleasure also govern the transition from casual behavior to behavior that a person cannot stop despite wanting to. This convergence explains why the DSM-5 reclassified gambling disorder alongside substance use disorders rather than impulse control disorders, and why drugs developed for diabetes are now being tested for addiction. Understanding how peptides control the brain's reward system reveals that compulsive behavior is not a failure of willpower. It is a shift in neurochemistry that multiple peptide systems either protect against or accelerate, and it is rooted in the same dopamine and peptide modulation circuitry that evolved to keep us alive.

Key Takeaways

At least five neuropeptide systems (opioid peptides, ghrelin, orexin, GLP-1, and oxytocin) converge on the brain's reward circuitry and influence compulsive behavior across food, substances, and gambling
Endogenous opioid peptides in the nucleus accumbens and VTA drive the pleasurable "liking" component of reward, and their dysregulation contributes to both binge eating and substance addiction
GLP-1 receptor agonists reduce binge eating episodes in clinical cases and reduce substance use across preclinical models of alcohol, nicotine, cocaine, and opioid self-administration
Ghrelin receptor (GHS-R1A) signaling promotes reward-seeking behavior for both food and drugs of abuse, with receptor antagonists reducing self-administration of alcohol, amphetamine, and cocaine in rodents
A 2025 study found that the endogenous opioid system is involved in binge eating, food devaluation, and compulsive-like eating behavior through distinct receptor-mediated pathways
Orexin receptor antagonists are emerging as potential treatments for opioid use disorder, with clinical trials demonstrating benefits for craving, withdrawal, and sleep disturbances

The Biology of Compulsion: From Impulse to Compulsion

Compulsive behavior differs from impulsive behavior in a specific neurobiological way. Impulsive actions are driven by the anticipation of reward: the brain expects something pleasurable and acts to obtain it. Compulsive actions persist despite diminishing reward or increasing negative consequences. The shift from impulse to compulsion involves measurable changes in neuropeptide signaling within the striatum, amygdala, and prefrontal cortex.^[1]

In addiction neuroscience, this transition is described as a shift from positive reinforcement (seeking pleasure) to negative reinforcement (avoiding withdrawal and distress). Neuropeptides are central to both phases. Endorphins and enkephalins drive the initial pleasure. Dynorphin and CRF drive the aversive withdrawal state that maintains compulsive use. The same framework applies whether the compulsive behavior involves heroin, slot machines, or late-night refrigerator raids.

Endogenous Opioid Peptides: The "Liking" System

The opioid peptide system is the most extensively studied neuropeptide network in compulsive behavior. Three families of opioid peptides (endorphins, enkephalins, and dynorphins) act through three primary receptor subtypes (mu, delta, and kappa) distributed throughout the reward circuitry.^[2]

Mu-opioid receptor activation in the nucleus accumbens shell generates hedonic "liking" responses to palatable food, drugs, and other rewarding stimuli. This system does not simply signal pleasure; it amplifies the perceived value of a reward, making it more likely to be sought again. Repeated activation leads to neuroadaptation: the system requires more stimulation to produce the same response, driving escalation.

A 2025 study mapped the involvement of the endogenous opioid system specifically in binge eating and compulsive-like eating behavior. The research found that distinct opioid receptor pathways mediate different components: mu receptors drive food palatability and consumption, while kappa receptor activation contributes to the negative emotional states that perpetuate compulsive eating cycles.^[3]

The opioid and endocannabinoid systems interact extensively in reward processing, with both systems converging on the same ventral tegmental area (VTA) dopamine neurons. Blocking one system partially compensates through the other, which is why single-target therapies for compulsive behavior often show limited efficacy.^[4]

Ghrelin: The Hunger Hormone That Drives Drug Seeking

Ghrelin, the stomach-derived "hunger hormone," activates growth hormone secretagogue receptors (GHS-R1A) in the VTA and nucleus accumbens, the same regions that process drug reward. This shared neuroanatomy means ghrelin does not just make food rewarding; it enhances the rewarding properties of drugs of abuse.

A 2022 review consolidated evidence that GHS-R1A signaling promotes reward-seeking behavior for alcohol, amphetamine, cocaine, and nicotine in rodent models. Ghrelin receptor antagonists reduced self-administration and cue-induced reinstatement (a model of relapse) across multiple drug classes.^[5]

The mechanism involves ghrelin's ability to potentiate dopamine release in the nucleus accumbens. When ghrelin levels are high (during fasting or stress), the reward value of both food and drugs increases. This creates a biological link between hunger, stress, and vulnerability to compulsive substance use, which is explored further in the article on ghrelin and alcohol craving.

A 2023 study demonstrated that neuropeptides including ghrelin, NPY, and AgRP modulate feeding behavior specifically through the dopamine reward pathway, with orexigenic peptides enhancing and anorexigenic peptides suppressing dopaminergic signaling in the VTA-nucleus accumbens circuit.^[6]

GLP-1: From Diabetes Drug to Anti-Compulsion Agent

The most clinically actionable finding in this field is that GLP-1 receptor agonists reduce compulsive behavior across multiple domains. GLP-1 receptors are expressed in the VTA, nucleus accumbens, and lateral septum, positioning the system to modulate reward processing directly.

In preclinical models, GLP-1 agonists reduce self-administration of alcohol, nicotine, cocaine, and opioids. A 2024 review examined the emerging evidence for GLP-1 receptor agonists across substance use disorders and behavioral addictions, noting consistent reductions in drug seeking across species and drug classes.^[7]

Clinical evidence is building for binge eating disorder specifically. A 2023 case report documented successful treatment of binge eating disorder with semaglutide, with the patient experiencing a reduction in binge episodes and food-related compulsive thoughts.^[8] A 2024 review found that GLP-1 receptor agonists represent a novel pharmacotherapy for binge eating, with clinical data showing reductions in binge frequency, body weight, and eating disorder psychopathology.^[9]

A 2025 review examined the neurobiological mechanisms underlying GLP-1's anti-addiction effects, identifying direct modulation of mesolimbic dopamine signaling, reduced reward anticipation, and attenuation of stress-induced reinstatement as potential pathways.^[10] Whether these effects translate beyond weight management into treating addiction broadly remains under active investigation, with the GLP-1 and compulsive behavior literature growing rapidly.

Orexin: The Wakefulness Peptide That Fuels Drug Seeking

Orexin (also called hypocretin), produced by neurons in the lateral hypothalamus, regulates wakefulness, arousal, and motivated behavior. Orexin neurons project directly to VTA dopamine neurons and to the nucleus accumbens, where they enhance dopamine release and strengthen drug-associated memories.

Orexin signaling is activated by drug-associated cues, stress, and contexts linked to prior drug use. Blocking orexin receptors with antagonists reduces cue-induced reinstatement of drug seeking for cocaine, alcohol, and opioids in rodent models. The dual orexin receptor antagonist suvorexant (FDA-approved for insomnia) has entered clinical trials for opioid use disorder, with early results showing reductions in opioid craving, withdrawal symptoms, and sleep disturbance.^[11]

Orexin's role in compulsive behavior extends beyond substance use. The peptide system is activated during anticipatory reward states, meaning it drives the "wanting" component of motivation. Dysregulated orexin signaling may contribute to compulsive gambling and compulsive internet use through the same arousal-reward coupling mechanism.

Oxytocin, primarily known for its role in social bonding, also modulates the reward system. A 2022 study assessed reward-related brain function after a single dose of oxytocin using fMRI, finding that intranasal oxytocin altered neural responses to reward anticipation and delivery in regions including the ventral striatum.^[12]

Oxytocin's anti-compulsive effects are hypothesized to work through social reward substitution: by enhancing the rewarding value of social interactions, oxytocin may reduce the relative reward value of drugs, food, or gambling. This mechanism differs from other neuropeptide interventions that directly dampen reward signaling.

The Emerging Peptide: LEAP2 and Impulsivity

Liver-expressed antimicrobial peptide 2 (LEAP2), an endogenous antagonist of the ghrelin receptor, is emerging as a player in compulsive behavior. A 2026 study examined LEAP2's role in cognitive impulsivity after refeeding, finding that LEAP2 modulated impulsive decision-making through ghrelin receptor blockade. This positions the ghrelin-LEAP2 axis as a bidirectional regulator of compulsive food seeking.^[13]

The convergence of multiple neuropeptide systems on the same reward circuitry explains several clinical observations:

Comorbidity: Compulsive eating, substance use, and gambling frequently co-occur. Between 20-50% of individuals with substance use disorders also meet criteria for an eating disorder. This is not coincidence; it reflects shared neuropeptide dysregulation in overlapping brain circuits.

Cross-sensitization: Repeated exposure to one rewarding stimulus (such as high-fat food) can sensitize the reward system to respond more strongly to other stimuli (such as drugs). Neuropeptide adaptations in the opioid, ghrelin, and orexin systems mediate this cross-sensitization.

Substitution: When one compulsive behavior is blocked (through gastric bypass surgery, for example), another may emerge. Post-bariatric surgery increases in alcohol use disorder rates reflect the brain's attempt to restore reward homeostasis through alternative neuropeptide-driven pathways.

Opponent process theory: Koob's influential model of addiction describes how the initial positive reward state (driven by opioid peptides and dopamine) is progressively opposed by a negative emotional state (driven by dynorphin and CRF). This opponent process operates identically in substance addiction and behavioral addictions, because the underlying peptide machinery is the same.^[1]

Where This Research Points

The peptide biology of compulsive behavior suggests that effective treatments need to address multiple systems simultaneously. GLP-1 agonists are the closest to clinical application for behavioral compulsions beyond their metabolic indications. Orexin antagonists are in clinical trials for opioid use disorder. Ghrelin receptor antagonists remain preclinical. Opioid system modulators (naltrexone, nalmefene) are already approved for alcohol use disorder and have shown some efficacy in binge eating.

The shared neuropeptide foundation of compulsive behaviors is not a theoretical abstraction. It explains why the same drugs keep showing up across seemingly unrelated conditions, why patients with one compulsive disorder are at risk for others, and why treating compulsive behavior requires understanding the full peptide landscape of the reward system rather than targeting any single molecule.

The Bottom Line

Compulsive behaviors across food, substances, and gambling share a common neuropeptide biology. Endogenous opioid peptides, ghrelin, orexin, GLP-1, and oxytocin all converge on the brain's reward circuitry, and dysregulation in these systems drives the transition from voluntary to compulsive behavior. GLP-1 receptor agonists and orexin antagonists are the most advanced clinical candidates for treating compulsive behaviors beyond their original indications.

Frequently Asked Questions

At least five neuropeptide systems are involved: endogenous opioid peptides (endorphins, enkephalins, dynorphins), ghrelin, orexin/hypocretin, GLP-1, and oxytocin. Each acts on the brain's reward circuitry through the ventral tegmental area and nucleus accumbens. Opioid peptides drive the pleasurable "liking" of rewards, ghrelin enhances reward salience during hunger, orexin links arousal to reward seeking, GLP-1 modulates reward anticipation, and oxytocin provides competing social reward signals.

Clinical evidence is emerging. A 2023 case report documented successful treatment of binge eating disorder with semaglutide, and a 2024 review found GLP-1 receptor agonists reduce binge frequency and eating disorder psychopathology. GLP-1 receptors in the brain's reward centers appear to directly modulate compulsive eating behavior. Clinical trials are ongoing, and no GLP-1 drug has FDA approval specifically for binge eating disorder as of 2026.

Both food and drug rewards activate the same mesolimbic dopamine pathway, modulated by the same neuropeptide systems. Opioid peptides in the nucleus accumbens enhance the pleasure of both palatable food and drugs. Ghrelin increases the reward value of both food and drugs through shared VTA mechanisms. This overlap explains why 20-50% of people with substance use disorders also have eating disorders and why treatments like GLP-1 agonists affect both.

The DSM-5 reclassified gambling disorder as an addictive disorder (rather than an impulse control disorder) based on shared neurobiology. Gambling activates the same reward circuitry, produces similar neuropeptide adaptations (reduced opioid receptor density, altered dopamine signaling), and responds to some of the same treatments (naltrexone, an opioid antagonist). The behavioral expression differs, but the underlying peptide-driven reward dysregulation overlaps substantially.

Ghrelin enhances the rewarding properties of drugs by activating growth hormone secretagogue receptors (GHS-R1A) in the VTA and nucleus accumbens. In rodent models, ghrelin increases self-administration of alcohol, amphetamine, cocaine, and nicotine. Ghrelin receptor antagonists reduce drug seeking and cue-induced reinstatement across drug classes. The effect is strongest during fasting or stress, when ghrelin levels are naturally elevated.

Early clinical evidence is promising. Dual orexin receptor antagonists (DORAs) like suvorexant, already FDA-approved for insomnia, have entered clinical trials for opioid use disorder. Initial results show reductions in opioid craving, withdrawal symptoms, and sleep disturbances. Orexin neurons in the lateral hypothalamus project directly to reward-processing regions, and blocking orexin signaling reduces cue-induced drug seeking in preclinical models.